Novel therapeutic options in metastatic renal cancer - Review and Post ASCO 2007 update

Stephan Kruck; Markus A. Kuczyk; Georgios Gakis; Mario W. Kramer; Arnulf Stenzl; Axel S. Merseburger

doi:10.2174/157488708785700311

Novel therapeutic options in metastatic renal cancer - Review and Post ASCO 2007 update

Stephan Kruck, Markus A. Kuczyk^*, Georgios Gakis, Mario W. Kramer, Arnulf Stenzl, Axel S. Merseburger

^*Corresponding author for this work

Clinic of Urology

9 Citations (Scopus)

Abstract

Cytokine-based therapeutic approaches using interferon (IFN) and interleukin 2 (IL-2) were conventionally applied for the treatment of progressive RCC. Caused by the limited effectiveness of cytokine-based approaches in advanced renal cell carcinoma, new substances were needed. Among these, the "targeted therapies" particularly the group of the tyrosine kinase inhibitors, are of main interest. At present, multikinase inhibitors and antiangiogenic agents (VEGFR, PDGFR-beta, and mTOR) are used in first- and second-line therapies of metastatic RCC in various clinical studies. This review presents and discusses the effectiveness of the most frequently used substances in mono- or combination regimes based on current data of the ASCO 2007.

Original language	English
Journal	Reviews on recent clinical trials
Volume	3
Issue number	3
Pages (from-to)	212-216
Number of pages	5
ISSN	1574-8871
DOIs	https://doi.org/10.2174/157488708785700311
Publication status	Published - 09.2008

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2174/157488708785700311

Cite this

@article{e7bee6dc70d149aa90ce2d54ced12dc4,

title = "Novel therapeutic options in metastatic renal cancer - Review and Post ASCO 2007 update",

abstract = "Cytokine-based therapeutic approaches using interferon (IFN) and interleukin 2 (IL-2) were conventionally applied for the treatment of progressive RCC. Caused by the limited effectiveness of cytokine-based approaches in advanced renal cell carcinoma, new substances were needed. Among these, the {"}targeted therapies{"} particularly the group of the tyrosine kinase inhibitors, are of main interest. At present, multikinase inhibitors and antiangiogenic agents (VEGFR, PDGFR-beta, and mTOR) are used in first- and second-line therapies of metastatic RCC in various clinical studies. This review presents and discusses the effectiveness of the most frequently used substances in mono- or combination regimes based on current data of the ASCO 2007.",

author = "Stephan Kruck and Kuczyk, {Markus A.} and Georgios Gakis and Kramer, {Mario W.} and Arnulf Stenzl and Merseburger, {Axel S.}",

year = "2008",

month = sep,

doi = "10.2174/157488708785700311",

language = "English",

volume = "3",

pages = "212--216",

journal = "Reviews on recent clinical trials",

issn = "1574-8871",

number = "3",

}

TY - JOUR

T1 - Novel therapeutic options in metastatic renal cancer - Review and Post ASCO 2007 update

AU - Kruck, Stephan

AU - Kuczyk, Markus A.

AU - Gakis, Georgios

AU - Kramer, Mario W.

AU - Stenzl, Arnulf

AU - Merseburger, Axel S.

PY - 2008/9

Y1 - 2008/9

N2 - Cytokine-based therapeutic approaches using interferon (IFN) and interleukin 2 (IL-2) were conventionally applied for the treatment of progressive RCC. Caused by the limited effectiveness of cytokine-based approaches in advanced renal cell carcinoma, new substances were needed. Among these, the "targeted therapies" particularly the group of the tyrosine kinase inhibitors, are of main interest. At present, multikinase inhibitors and antiangiogenic agents (VEGFR, PDGFR-beta, and mTOR) are used in first- and second-line therapies of metastatic RCC in various clinical studies. This review presents and discusses the effectiveness of the most frequently used substances in mono- or combination regimes based on current data of the ASCO 2007.

AB - Cytokine-based therapeutic approaches using interferon (IFN) and interleukin 2 (IL-2) were conventionally applied for the treatment of progressive RCC. Caused by the limited effectiveness of cytokine-based approaches in advanced renal cell carcinoma, new substances were needed. Among these, the "targeted therapies" particularly the group of the tyrosine kinase inhibitors, are of main interest. At present, multikinase inhibitors and antiangiogenic agents (VEGFR, PDGFR-beta, and mTOR) are used in first- and second-line therapies of metastatic RCC in various clinical studies. This review presents and discusses the effectiveness of the most frequently used substances in mono- or combination regimes based on current data of the ASCO 2007.

UR - http://www.scopus.com/inward/record.url?scp=54049131744&partnerID=8YFLogxK

U2 - 10.2174/157488708785700311

DO - 10.2174/157488708785700311

M3 - Scientific review articles

C2 - 18782079

AN - SCOPUS:54049131744

SN - 1574-8871

VL - 3

SP - 212

EP - 216

JO - Reviews on recent clinical trials

JF - Reviews on recent clinical trials

IS - 3

ER -

Novel therapeutic options in metastatic renal cancer - Review and Post ASCO 2007 update

Abstract

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this